ArticleInsights into imaging2024
Ultra-high gradient performance 3-Tesla MRI for super-fast and high-quality prostate imaging: initial experience.
Article in Insights into imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06244680 (Super-fast 3T Prostate MRI Using High Gradient Strength and Deep Learning), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Super-fast 3T Prostate MRI Using High Gradient Strength and Deep Learning: Initial Experience
Who cites it
6 citing papers in PubMed.
- Restriction-Weighted Q-Space Trajectory Imaging (ResQ): Toward Mapping Diffusion-Time Effects With Tensor-Valued Diffusion Encoding in Human Prostate Cancer Xenografts.NMR in biomedicine · 2026Article
- MyoClass: A modular multimodal auto-classification system for myocardial tissue characterization.The international journal of cardiovascular imaging · 2026Article
- Microstructure imaging of prostate cancer by diffusion MRI.Magma (New York, N.Y.) · 2026Review
- Strong-Gradient Diffusion-Weighted Imaging of Prostate Cancer Using an Inside-Out Nonlinear Gradient Coil.Magnetic resonance in medicine · 2026Article
- Acquisition, image quality, and PI-RADS agreement of ultrahigh-gradient DWI in prostate 3-T MRI.European radiology experimental · 2026Article
- Distinguishing Hepatocellular Carcinoma from Cirrhotic Regenerative Nodules Using MR Cytometry.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo implement and evaluate a super-fast and high-quality biparametric MRI (bpMRI) protocol for prostate imaging acquired at a new ultra-high gradient 3.0-T MRI system.
methodsParticipants with clinically suspected prostate cancer prospectively underwent a multiparametric MRI (mpMRI) on a new 3.0-T MRI scanner (maximum gradient strength: 200 mT/m, maximum slew rate: 200 T/m/s). The bpMRI protocol was extracted from the full mpMRI protocol, including axial T2-weighted and diffusion-weighted (DWI) sequences (b0/800, b1500). Overall image quality was rated by two readers on a five-point Likert scale from (1) non-diagnostic to (5) excellent. PI-RADS 2.1 scores were assessed by three readers separately for the bpMRI and mpMRI protocols. Cohen's and Fleiss' κ were calculated for PI-RADS agreement between protocols and interrater reliability between readers, respectively.
resultsSeventy-seven male participants (mean age, 66 ± 8 years) were included. Acquisition time of the bpMRI protocol was reduced by 62% (bpMRI: 5 min, 33 ± 21 s; mpMRI: 14 min, 50 ± 42 s). The bpMRI protocol showed excellent overall image quality for both the T2-weighted (median score both readers: 5 [IQR: 4-5]) and DWI (b1500) sequence (median score reader 1: 4 [IQR: 4-5]; reader 2: 4 [IQR: 4-4]). PI-RADS score agreement between protocols was excellent (Cohen's κ range: 0.91-0.95 [95% CI: 0.89, 0.99]) with an overall good interrater reliability (Fleiss' κ, 0.86 [95% CI: 0.80, 0.92]).
conclusionUltra-high gradient MRI allows the establishment of a high-quality and rapidly acquired bpMRI with high PI-RADS agreement to a full mpMRI protocol. TRIALS REGISTRATION: Clinicaltrials.gov, NCT06244680, Registered 06 February 2024, retrospectively registered, https://classic. CLINICALTRIALS: gov/ct2/show/NCT06244680 . CRITICAL RELEVANCE STATEMENT: A novel 3.0-Tesla MRI system with an ultra-high gradient performance enabled high-quality biparametric prostate MRI in 5.5 min while achieving excellent PI-RADS agreement with a standard multiparametric protocol. KEY POINTS: Multi- and biparametric prostate MRIs were prospectively acquired utilizing a maximum gradient of 200 mT/m. Super-fast biparametric MRIs showed excellent image quality and had high PI-RADS agreement with multiparametric MRIs. Implementation of high gradient MRI in clinical routine allows accelerated and high-quality biparametric prostate examinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.